Elmer Berghorn

2.0k total citations · 1 hit paper
20 papers, 1.5k citations indexed

About

Elmer Berghorn is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Elmer Berghorn has authored 20 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Elmer Berghorn's work include Cancer Immunotherapy and Biomarkers (7 papers), Renal cell carcinoma treatment (5 papers) and Economic and Financial Impacts of Cancer (4 papers). Elmer Berghorn is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Renal cell carcinoma treatment (5 papers) and Economic and Financial Impacts of Cancer (4 papers). Elmer Berghorn collaborates with scholars based in United States, Germany and United Kingdom. Elmer Berghorn's co-authors include Richard L. Schilsky, Stacey Bain, Frederick H. Hausheer, Frank S. Lieberman, T. Griffin, B Osterwalder, Daniel R. Budman, Bruno Reigner, Neal J. Meropol and Stuart M. Lichtman and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Elmer Berghorn

20 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

2022 125 citations Xīn Gào, Howard A. Burris et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Elmer Berghorn

Since Specialization

Citations

This map shows the geographic impact of Elmer Berghorn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elmer Berghorn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elmer Berghorn more than expected).

Fields of papers citing papers by Elmer Berghorn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elmer Berghorn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elmer Berghorn. The network helps show where Elmer Berghorn may publish in the future.

Co-authorship network of co-authors of Elmer Berghorn

This figure shows the co-authorship network connecting the top 25 collaborators of Elmer Berghorn. A scholar is included among the top collaborators of Elmer Berghorn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elmer Berghorn. Elmer Berghorn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study. 2024 ·Journal of Clinical Oncology ·Daniel P. Petrylak, Meredith McKean, Joshua M. Lang, Xin Gao, Robert Dreicer, Daniel M. Geynisman, Tyler F. Stewart, Mitul Gandhi, Leonard J. Appleman, Tanya B. Dorff, Gurkamal Chatta, Ronald Tutrone, (unknown), Elmer Berghorn, Jiachang Gong, (unknown), (unknown), Edward D. Chan, Neal D. Shore	19
2	A phase 2 expansion study of ARV-766, a PROTACandrogen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC). 2023 ·Journal of Clinical Oncology ·Daniel P. Petrylak, Tyler F. Stewart, Xin Gao, Elmer Berghorn, Haolan Lu, Edward D. Chan, Richard Gedrich, Joshua M. Lang, Meredith McKean	29
3	Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). breakdown → 2022 ·Journal of Clinical Oncology ·Xīn Gào, Howard A. Burris, Jacqueline Vuky, Robert Dreicer, Oliver Sartor, Cora N. Sternberg, Ivor Percent, Maha Hussain, Arash Rezazadeh Kalebasty, John Shen, Elisabeth I. Heath, Guillermo Abesada‐Terk, Sunil Gandhi, Meredith McKean, Haolan Lu, Elmer Berghorn, Richard Gedrich, (unknown), Nicholas J. Vogelzang, Daniel P. Petrylak	125
4	Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study 2018 ·Journal for ImmunoTherapy of Cancer ·Asim Amin, Elizabeth R. Plimack, Marc S. Ernstoff, Lionel D. Lewis, Todd M. Bauer, David F. McDermott, Michael A. Carducci, Christian Kollmannsberger, Brian I. Rini, Daniel Y.C. Heng, Jennifer J. Knox, Martin H. Voss, Jennifer L. Spratlin, Elmer Berghorn, Lingfeng Yang, Hans J. Hammers	148
5	A phase III, randomized, placebo-controlled trial of adjuvant nivolumab plus ipilimumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after radical or partial nephrectomy (CheckMate 914) 2018 ·Annals of Oncology ·Axel Bex, Viktor Grünwald, Paul Russo, Yoshihiko Tomita, Elmer Berghorn, M. Brent McHenry, Robert J. Motzer	6
6	Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma 2017 ·European Journal of Cancer ·Birgit Geoerger, Christophe Bergeron, Lia Gore, Leonard S. Sender, Ira J. Dunkel, Cynthia E. Herzog, Liève Brochez, Ofelia Cruz, Karsten Nysom, Elmer Berghorn, Burçin Şimşek, Jun Shen, Alberto S. Pappo	57
7	Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study 2017 ·Japanese Journal of Clinical Oncology ·Yoshihiko Tomita, Satoshi Fukasawa, Nobuo Shinohara, Hiroshi Kitamura, Mototsugu Oya, Masatoshi Eto, Kazunari Tanabe, Go Kimura, Junji Yonese, Masahiro Yao, Robert J. Motzer, Hirotsugu Uemura, M. Brent McHenry, Elmer Berghorn, Seiichiro Ozono	52
8	Phase II study of ipilimumab (IPI) in children and adolescents with unresectable stage III or IV malignant melanoma (MEL). 2017 ·Journal of Clinical Oncology ·Alberto S. Pappo, Christophe Bergeron, Lia Gore, Leonard S. Sender, Ira J. Dunkel, Cynthia E. Herzog, Liève Brochez, Ofelia Cruz, Karsten Nysom, Elmer Berghorn, Burçin Şimşek, Jun Shen, Birgit Geoerger	1
9	Overall Survival, Health-Related Quality of Life, and Healthcare Resource Use: Independent Analyses from Checkmate 025, A Phase Iii Study of Nivolumab Versus Everolimus in Patients with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma 2016 ·Value in Health ·Fiona Taylor, Homa Dastani, Bryan Bennett, Michael DeRosa, Elmer Berghorn, (unknown)	2
10	Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial 2016 ·The Lancet Oncology ·David Cella, Viktor Grünwald, Paul Nathan, Justin Doan, Homa Dastani, Fiona Taylor, Bryan Bennett, Michael DeRosa, Scott Berry, Kristine Broglio, Elmer Berghorn, Robert J. Motzer	156
11	Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial 2016 ·The Lancet Oncology ·Jeffrey S. Weber, (unknown), Ryan J. Sullivan, Jeffrey A. Sosman, Craig L. Slingluff, Donald P. Lawrence, Theodore F. Logan, Lynn M. Schuchter, Suresh Nair, Leslie A. Fecher, Elizabeth I. Buchbinder, Elmer Berghorn, Mary Ruisi, George Kong, Joel Jiang, Christine E. Horak, F. Stephen Hodi	257
12	Quality of life (QoL) and overall survival (OS) in patients (pts) with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs. everolimus (EVE) in the phase III CheckMate 025 study. 2016 ·Journal of Clinical Oncology ·David Cella, Viktor Gruenwald, Paul Nathan, Justin Doan, Homa Dastani, Fiona Taylor, Bryan Bennett, Michael DeRosa, Scott Berry, Kristine Broglio, Elmer Berghorn, Robert J. Motzer	4
13	Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors 2013 ·Cancer Chemotherapy and Pharmacology ·John F. Deeken, (unknown), André Liem, David P. Hill, Jayne S. Gurtler, Elmer Berghorn, (unknown), Haolan Lu, Ovidiu C. Trifan, (unknown)	14
14	Diagnosis, Management, and Evaluation of Chemotherapy-Induced Peripheral Neuropathy 2006 ·Seminars in Oncology ·Frederick H. Hausheer, Richard L. Schilsky, Stacey Bain, Elmer Berghorn, Frank S. Lieberman	307
15	Phase II Trial of Karenitecin in Patients with Malignant Melanoma: Clinical and Translational Study 2005 ·Clinical Cancer Research ·Adil Daud, Nikola Valkov, Barbara A. Centeno, (unknown), Patricia Sullivan, Pamela N. Münster, P. Urbas, Ronald C. DeConti, Elmer Berghorn, Zhen-Mei Liu, (unknown), Daniel M. Sullivan	57
16	Phase II trial of karenitecin (BNP1350) in malignant: Clinical and translational study 2004 ·Journal of Clinical Oncology ·F. H. Hausheer, Elmer Berghorn, (unknown), Daniel M. Sullivan, Barbara A. Centeno, (unknown), Ronald C. DeConti, Adil Daud, Patricia Sullivan, Stephanie Andrews	1
17	Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. 1998 ·Journal of Clinical Oncology ·Daniel R. Budman, Neal J. Meropol, Bruno Reigner, (unknown), Stuart M. Lichtman, Elmer Berghorn, (unknown), (unknown), B Osterwalder, T. Griffin	221
18	Unusual central nervous system toxicity in a phase I study of N1N11diethylnorspermine in patients with advanced malignancy 1997 ·Investigational New Drugs ·Patrick J. Creaven, Raymond P. Perez, Lakshmi Pendyala, Neal J. Meropol, Gregory Loewen, Ellis Levine, Elmer Berghorn, Derek Raghavan	45
19	Paclitaxel and carboplatin in early phase studies: Roswell Park Cancer Institute experience in the subset of patients with lung cancer. 1997 ·PubMed ·Patrick J. Creaven, Derek Raghavan, Lakshmi Pendyala, Gregory Loewen, Hedy L. Kindler, Elmer Berghorn	2
20	A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patients with colorectal carcinoma 1995 ·Investigational New Drugs ·Neal J. Meropol, (unknown), Youcef M. Rustum, Miguel A. Rodrı́guez-Bigas, Leslie E. Blumenson, Cheryl Frank, Elmer Berghorn, Patrick J. Creaven	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact